UK pharma manufacturing: the giants' margins are set in head office, not the market

The two most instructive margins in British pharmaceutical manufacturing belong to Ipsen Biopharm and Eli Lilly and Company Limited. Ipsen’s UK operation — anchored by the French drugmaker’s biologics plant in Wrexham — kept £253.0M of pre-tax profit on £660.8M of turnover, a 38% margin. Lilly’s UK company kept £51.8M on £889.0M, about 6% — in a year its revenue grew 90% on the back of the GLP-1 wave. Neither number was earned in a market. Both companies sell almost entirely to and through their own global groups, and what the UK entity “makes” is whatever the group’s transfer-pricing agreement allocates to it. That is the defining fact of this category: among the 155 UK pharmaceutical manufacturing companies that publish a full profit-and-loss — £19.3bn of combined turnover — most of the revenue at the top sits in the UK arms and captive plants of global pharma, where margin is head-office arithmetic, not performance. The biggest name of all, AAH Pharmaceuticals at £2.96bn, doesn’t manufacture medicines at all — it distributes them. The genuine market signal lives further down, in a mid-market of contract manufacturers, sterile-specials houses and niche-medicine owners where margins really are won and lost. Figures are approximate — verify against a company’s own accounts before relying on any single number.

Read the register first

Three things change how you read every number below.

The biggest company in the category is a wholesaler. AAH Pharmaceuticals — one of Britain’s largest medicines distributors, delivering to pharmacies nationwide — sits at the top with £2.96bn of turnover and £56.1M of profit, a 1.9% margin. That is classic medicine-distribution economics, and its story belongs with the pharma wholesale market, where the national networks run at 1–2% by design. It is excluded from every manufacturing read below; strip it out and the category is nearer a £16.3bn industry.

Most of the remaining giants are group vehicles, not competitors. Novartis, Baxter, Boehringer Ingelheim and Lilly appear here through UK trading arms whose revenue is the group’s UK medicine sales and whose margin is set by intercompany agreement — typically a thin, stable cost-plus number. The captive plants run the same logic in reverse: Ipsen Biopharm’s 38% and Indivior UK’s 20% reflect where their groups choose to book profit on medicines made here and sold worldwide. None of these margins can be compared with each other, or with an independent’s.

One giant is real — and global. Hikma Pharmaceuticals, the London-listed generics and injectables group, made £484.6M of pre-tax profit on £2.51bn — a 19% margin earned in actual markets, though that is profit before a one-off legal settlement; statutory reported PBT was lower (nearer 15.5%). But its accounts consolidate operations across the Middle East, North Africa, the US and Europe; the UK is its listing and headquarters, not the location of most of those 9,603 staff.

The giants: mostly other people’s arithmetic

…and 145 more with a full profit-and-loss. Patheon UK — the contract-manufacturing business inside Thermo Fisher’s group — books £813.3M through 444 staff, far more revenue than one site’s output; much of it is intercompany supply, and its 17% margin should be read accordingly. Watch the headcount column against revenue generally: Indivior UK puts £547.4M through 192 people. These are booking entities as much as factories.

The contrast at the top is the whole report. Read down the profit column and the highest margins belong to the companies with the least market exposure — the captive plants — while the group trading arms cluster at 5–8% no matter what happens to their revenue. Lilly is the clean experiment: turnover up 90% in a year, margin unchanged at ~6%. In a genuine business that operating leverage would have shown up somewhere; in a transfer-priced one, the extra profit lands wherever the group wants it.

The shape of the market

The size distribution is barrel-shaped in a way few industries are: 31 companies under £1M — licence-holding vehicles, early-stage ventures, dormant-adjacent entities — then almost nothing (three companies) between £1M and £5M, then a broad, prosperous middle. Pharmaceutical manufacture has a minimum viable scale: a licensed facility, quality systems, regulatory staff. You are either a plant or a shell, and the accounts show it — profitability climbs from 39% in the sub-£1M tail to 81% in the £25–100M band and 92% above £100M.

The operators worth studying

Filter out the group arms, the wholesaler and the mis-filed neighbours, and a genuinely instructive mid-market emerges. It splits into two business models — and the split is the margin story:

• Making medicines for a fee — contract manufacturers earn honest but bounded margins: Thompson & Capper, the Runcorn contract maker of tablets and capsules, at 11.1%; Nova Laboratories, the Leicester sterile-specials house, at 18.3%.
• Owning the medicine — companies that hold their own product licences keep two to four times as much: Cycle Group Holdings, the Cambridge rare-disease medicines specialist, at 29.5% and growing; Essential Pharma at 20.2%; Chemidex Pharma at 20.8% and growing. At the top of the range sit the specialist biologicals houses — Sartorius Albumedix, the Nottingham recombinant-albumin maker, at 46.2%, and RSR, the Cardiff producer of diagnostic antigens and antibodies, at a headline 69.6% — where the product is the intellectual property. RSR’s ratio needs unpacking, though: nearly half of its profit (~£8.4M of £18.5M) is royalty income on its patented IP, booked outside the turnover line, which mechanically inflates profit-on-turnover; its trading margin ex-royalties is nearer 36% — a licence-owner margin, not a number to set against a contract manufacturer’s 11%.

Held out of this read: Watson-Marlow (£93.0M at 18.2% — peristaltic pumps and fluid-path equipment for biopharma processing, an engineering business, not a drugmaker); Herrco Cosmetics and G. & M. Procter (cosmetics contract manufacturers); T.G. Eakin, Terumo BCT and Medlock Medical (medical devices and wound care); and LRC Products, whose 85.7% margin on £73.8M with no reported staff is the fingerprint of a brand/IP-holding entity inside a consumer-goods group, not a factory. Bespak HC stays in the table — a genuine King’s Lynn drug-delivery manufacturer — but note the trajectory: strong margin, shrinking revenue and headcount. RSR’s 69.6% needs its own caveat: ~£8.4M of its £18.5M profit (46%) is royalty income on patented IP, booked as other operating income below the turnover line — its trading margin is far lower (operating margin ex-royalties ~36%), so the ratio reflects IP licensing, not the profitability of making a product.

Growth, read with care

The growth table is where Britain’s next pharmaceutical infrastructure is visible — none of it reads like ordinary trading growth. Autolus’s +1,910% to £8.0M is a cell-therapy developer booking its first commercial revenue while spending like the clinical-stage biotech it still mostly is (−£180.5M pre-tax); its story belongs with the biotech map. Moderna Biotech Manufacturing UK is the register’s newest plant: +912% to £47.5M with headcount up 16-fold as the company’s UK vaccine-manufacturing site ramps — a build-out, not a business yet, and the small loss is the intended cost of it. And Eli Lilly’s +90% at scale is the GLP-1 boom arriving through a UK trading arm — real demand, but remember the margin never moves. The rest of the table is mostly low-base rebounds and brand acquisitions; the staff-backed rows (Hectic Lifestyles +61% revenue / +43% staff, New Nordic +63% / +67%) are consumer-health brand businesses rather than drugmakers.

Market structure and vintage

On paper the top five hold 41.1% of the £19.3bn and the top ten 54.9% — but the curve is padded with other people’s business: the wholesaler, the group trading arms, a globally consolidated plc. The genuinely competitive layer — independent manufacturers and licence owners — is a broad £5–100M mid-market of 82 companies with no dominant player, which is why the contract manufacturers among them can hold double-digit margins: capacity is scarce and switching a licensed manufacturing site is slow and regulated.

The vintage profile is old: 59 of the 155 pre-date 1990, because a licensed pharmaceutical plant is the kind of asset that persists for generations under changing owners. The young tail is small but telling — 10 companies incorporated since 2021 include Moderna’s UK manufacturing entity, vaccine-era infrastructure arriving on the register. Ownership skews corporate (100 of 155), and about 19 carry Holdings/Group/Bidco-style names — the structural fingerprint of buyout ownership, visible at the quality end of the mid-market (Cycle Group Holdings, Bespak HC, Nelson & Russell Holdings): the licence-owning specialists are exactly what private equity likes to buy.

What the map shows

1. At the top, margin is transfer-pricing arithmetic, not performance. Ipsen’s UK plant keeps 38%; Lilly’s UK arm keeps ~6% even as revenue grows 90%. The difference is where each group chooses to book profit — none of it is comparable with an independent’s margin.
2. The biggest “manufacturer” is a wholesaler. AAH Pharmaceuticals’ £2.96bn at 1.9% is medicine-distribution economics — its story is in the pharma wholesale map. Strip it and this is a ~£16.3bn category.
3. Hikma is the one giant earning a market margin — £484.6M on £2.51bn (19%) as a listed generics and injectables group — but its accounts consolidate a global business, not a UK one.
4. Owning the medicine beats making it for a fee. Licence owners (Cycle 29.5%, Chemidex 20.8%, Essential Pharma 20.2%) and specialist biologicals houses (Sartorius Albumedix 46.2%, RSR 69.6% — though ~£8.4M of RSR’s profit is royalty income booked outside turnover, so its trading margin is far lower) keep two to four times the margin of contract manufacturers (Thompson & Capper 11.1%).
5. Britain’s next pharma infrastructure is visible in the growth table — Moderna’s new plant ramping with headcount up 16-fold, Autolus booking its first cell-therapy revenue against a £180.5M loss, and the GLP-1 wave arriving through Lilly’s UK arm.
6. There is almost nothing between £1M and £5M. Pharmaceutical manufacture has a minimum viable scale; the register is licensed plants and shells, with barely a cottage tier in between.

Methodology and caveats

This covers only the UK pharmaceutical manufacturing companies that publish a full profit-and-loss — 155 of a register of 278; the rest file abridged or dormant accounts and don’t appear. The category mixes at least four revenue models — global groups’ UK trading arms and captive plants (margins set by intercompany agreement), independent licence owners, fee-based contract manufacturers, and brand/IP-holding entities — and margins are never comparable across them; we have flagged which is which rather than ranking them on one scale. A number of neighbours are mis-filed into the category (a medicines wholesaler, cosmetics contract manufacturers, medical-device makers, a fluid-handling engineer) and are excluded from competitive reads but remain in the headline totals, so the £19.3bn category total overstates genuine medicine manufacture — nearer £16.3bn without the wholesaler alone. Hikma’s accounts consolidate its worldwide operations and are prepared in US dollars, as are those of some other overseas-parented filers; their sterling figures here are converted at the average rate for the period, so the numbers in their own accounts will read larger in dollars. Each row uses the latest accounts available when the data was assembled, and newer accounts may since have appeared. Business-type labels are directional. Figures are approximate — this is analysis, not financial advice; verify any specific figure against the company’s own accounts.